Is cerebral involvement an occasional feature of muscle-specific kinase antibody-positive syndrome?
S
S
Bhagavati
P J
PJ
Maccabee
G
G
Chari
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001323:Autoantibodies / Q000032:analysis / Q000097:blood*; D001921:Brain / Q000276:immunology* / Q000503:physiopathology*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004569:Electroencephalography; D004827:Epilepsy / Q000276:immunology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008569:Memory Disorders / Q000276:immunology / Q000503:physiopathology; D018908:Muscle Weakness / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000276:immunology / Q000294:innervation / Q000503:physiopathology; D009157:Myasthenia Gravis / Q000150:complications* / Q000276:immunology / Q000503:physiopathology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology*; D011950:Receptors, Cholinergic / Q000276:immunology*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001323:Autoantibodies; D002800:Cholinesterase Inhibitors; D016756:Immunoglobulins, Intravenous; D011950:Receptors, Cholinergic; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases; D009173:Mycophenolic Acid; D011729:Pyridostigmine Bromide; D011241:Prednisone